Adrian, Derek
King, Jonathan N.
Parrish, Rudolph S.
King, Stephen B.
C. Budsberg, Steven
Gruen, Margaret E.
Lascelles, B. Duncan X.
Funding for this research was provided by:
Elanco Animal Health (557917, 557917, 557917, 557917, 557917, 557917, 557917)
Article History
Received: 22 September 2020
Accepted: 23 March 2021
First Online: 8 April 2021
Competing interests
: The study was funded initially by Novartis Animal Health and later (after its acquisition) by Elanco Animal Health, which manufacture and distribute robenacoxib (Onsior) tablets. DA was a graduate student in the TRiP program at the time of the study and is now employed by Elanco Animal Health. JNK and SBK are employed and RSP was previously employed by Elanco Animal Health. BDXL and SCB have received consultancy fees and honoraria for lecturing (including reimbursement for travel and accommodations) on behalf of Novartis Animal Health and Elanco Animal Health. MEG has no conflicts of interest to declare.